company background image
EUK

EuKedos BIT:EUK Stock Report

Last Price

€1.42

Market Cap

€32.2m

7D

9.3%

1Y

12.3%

Updated

07 Aug, 2022

Data

Company Financials
EUK fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health1/6
Dividends0/6

EUK Stock Overview

EuKedos S.p.A. provides managed and long-term care services in Italy.

EuKedos Competitors

Price History & Performance

Summary of all time highs, changes and price drops for EuKedos
Historical stock prices
Current Share Price€1.42
52 Week High€3.50
52 Week Low€1.16
Beta0.011
1 Month Change4.81%
3 Month Change-4.39%
1 Year Change12.30%
3 Year Change36.06%
5 Year Change34.76%
Change since IPO-98.88%

Recent News & Updates

May 03
Is EuKedos (BIT:EUK) Using Too Much Debt?

Is EuKedos (BIT:EUK) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Mar 07
Here's What To Make Of EuKedos' (BIT:EUK) Decelerating Rates Of Return

Here's What To Make Of EuKedos' (BIT:EUK) Decelerating Rates Of Return

There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll want...

Shareholder Returns

EUKIT HealthcareIT Market
7D9.3%-5.3%0.5%
1Y12.3%-27.4%-15.3%

Return vs Industry: EUK exceeded the Italian Healthcare industry which returned -27.4% over the past year.

Return vs Market: EUK exceeded the Italian Market which returned -15.3% over the past year.

Price Volatility

Is EUK's price volatile compared to industry and market?
EUK volatility
EUK Average Weekly Movement7.4%
Healthcare Industry Average Movement6.5%
Market Average Movement5.1%
10% most volatile stocks in IT Market7.8%
10% least volatile stocks in IT Market3.2%

Stable Share Price: EUK is more volatile than 75% of Italian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: EUK's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Italian stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a590Carlo Iuculanohttps://www.eukedos.it

EuKedos S.p.A. provides managed and long-term care services in Italy. The company offers residential social care services to elderly, self-sufficient, or incapacitated adults. It manages healthcare and assistance residences with 1,345 beds in the North and Central Italy, primarily located in Lombardy, Piedmont, Abruzzo, Valle D'Aosta, and Emilia Romagna.

EuKedos Fundamentals Summary

How do EuKedos's earnings and revenue compare to its market cap?
EUK fundamental statistics
Market Cap€32.18m
Earnings (TTM)€570.00k
Revenue (TTM)€43.98m

56.5x

P/E Ratio

0.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EUK income statement (TTM)
Revenue€43.98m
Cost of Revenue€33.25m
Gross Profit€10.73m
Other Expenses€10.16m
Earnings€570.00k

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.025
Gross Margin24.39%
Net Profit Margin1.30%
Debt/Equity Ratio66.1%

How did EUK perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is EUK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EUK?

Other financial metrics that can be useful for relative valuation.

EUK key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3x
Enterprise Value/EBITDA25.3x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does EUK's PE Ratio compare to its peers?

EUK PE Ratio vs Peers
The above table shows the PE ratio for EUK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average19.6x
SRI Servizi Italia
6.4x20.4%€38.8m
HI Health Italia
24.1xn/a€30.3m
SVS Svas Biosana
19.5x22.0%€61.6m
MDC Medica
28.5x20.7%€141.9m
EUK EuKedos
56.5xn/a€32.2m

Price-To-Earnings vs Peers: EUK is expensive based on its Price-To-Earnings Ratio (56.5x) compared to the peer average (19.6x).


Price to Earnings Ratio vs Industry

How does EUK's PE Ratio compare vs other companies in the European Healthcare Industry?

Price-To-Earnings vs Industry: EUK is expensive based on its Price-To-Earnings Ratio (56.5x) compared to the Italian Healthcare industry average (24.1x)


Price to Earnings Ratio vs Fair Ratio

What is EUK's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EUK PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio56.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate EUK's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of EUK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EUK (€1.42) is trading above our estimate of fair value (€0.67)

Significantly Below Fair Value: EUK is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is EuKedos forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


16.1%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as EuKedos has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of EUK’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • EuKedos competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has EuKedos performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-3.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: EUK has a large one-off gain of €1.0M impacting its December 31 2021 financial results.

Growing Profit Margin: EUK became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: EUK has become profitable over the past 5 years, growing earnings by -3.5% per year.

Accelerating Growth: EUK has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: EUK has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (26.6%).


Return on Equity

High ROE: EUK's Return on Equity (2%) is considered low.


Discover strong past performing companies

Financial Health

How is EuKedos's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: EUK's short term assets (€13.6M) do not cover its short term liabilities (€16.5M).

Long Term Liabilities: EUK's short term assets (€13.6M) do not cover its long term liabilities (€104.8M).


Debt to Equity History and Analysis

Debt Level: EUK's net debt to equity ratio (40.4%) is considered high.

Reducing Debt: EUK's debt to equity ratio has increased from 63.3% to 66.1% over the past 5 years.

Debt Coverage: EUK's debt is well covered by operating cash flow (29.5%).

Interest Coverage: EUK's interest payments on its debt are not well covered by EBIT (1.1x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is EuKedos's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate EUK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EUK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EUK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EUK's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: EUK is not paying a notable dividend for the Italian market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as EUK has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

9.2yrs

Average management tenure


CEO

Carlo Iuculano (60 yo)

9.17yrs

Tenure

€236,044

Compensation

Mr. Carlo Iuculano has been the Chairman at EuKedos S.p.A. since November 4, 2011 and has been its Chief Executive Officer since June 20, 2013 and also served as its President. Mr. Iuculano served as a Man...


CEO Compensation Analysis

Compensation vs Market: Carlo's total compensation ($USD239.74K) is below average for companies of similar size in the Italian market ($USD363.91K).

Compensation vs Earnings: Carlo's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: EUK's management team is seasoned and experienced (9.2 years average tenure).


Board Members

Experienced Board: EUK's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

EuKedos S.p.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: EuKedos S.p.A.
  • Ticker: EUK
  • Exchange: BIT
  • Founded: NaN
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: €32.179m
  • Shares outstanding: 22.74m
  • Website: https://www.eukedos.it

Number of Employees


Location

  • EuKedos S.p.A.
  • Via Benedetto Da Foiano, 14
  • Florence
  • Florence
  • 50125
  • Italy

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/07 00:00
End of Day Share Price2022/08/05 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.